FDA is defining proper social media use in small doses, through warning letters and minor rule changes, rather than issuing comprehensive guidance, as illustrated in a recent warning that targets a company’s “likes.”
Since 2009, FDA has promised to issue guidance on how drug firms can use social media safely, but multiple delays prompted Congress to add a provision to the FDA Safety and Innovation Act, signed into law last summer, mandating the agency issue guidance on
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?